LQDA
LiquidiaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The post-earnings read-through improved: secondary follow-up coverage indicated Q1 revenue and EPS beat consensus, and at least two analysts reportedly raised targets to about $59-$60 after the print, which is more constructive than the stale packet median target of $45.7. The main bull argument is that YUTREPIA launch depth, prescriber expansion, and positive EBITDA are arriving faster than a typical small-cap biopharma commercialization curve.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.3.
What can break
Commercial expectations are now higher after a strong Q1; sustaining launch growth at a much larger revenue base is harder, especially as SG&A rose materially with the commercial buildout [#8-K-2026-05-11].
Momentum
96
Value
48
Sentiment
16
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $56.00 · Bull $68.00 · Bear $38.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $74.25
Why
Momentum96 · Δ7d -0.3
Value48 · Δ7d -0.1
Sentiment16 · Δ7d -3.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendImproving
Δ7d
-0.3
Δ21d
-0.7
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
16
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
-2.8
Why this grade
Composite grade C. Momentum 95.8 / Value 48.5 / Sentiment 15.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$7.11B
Beta
0.47
Shares Out
88.93M
P/E (TTM) · Derived
-99.8
P/S (TTM)
40.41
P/FCF (TTM) · Derived
249.34
Rev YoY
+4158.5%
EPS YoY
-216.0%
Gross Margin
+91.5%
Op Margin
-155.0%
Net Debt
$7.25M
Current Ratio
2.22
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology